8-K filed January 7, 2026, 6:59 PM ET ticker KYNB CIK 0000921299

other material confidence high sentiment positive materiality 0.75

FibroGen rebrands as Kyntra Bio; new ticker KYNB effective Jan 8; pipeline milestones detailed

KYNTRA BIO, INC.

Name changed to Kyntra Bio, Inc. via Certificate of Amendment effective 4:30pm ET Jan 7, 2026.
Common stock to trade under symbol KYNB on Nasdaq at market open Jan 8, 2026; CUSIP unchanged.
CEO cites sale of FibroGen China, payoff of term loan, and cash runway extended into 2028.
FG-3246 Phase 2 monotherapy interim results expected H2 2026; topline Phase 1b/2 combo at ASCO GU Q1 2026.
Roxadustat granted FDA Orphan Drug Designation for MDS; pivotal Phase 3 protocol submitted.

item 5.03 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-006327
form_type: 8-K
ticker: KYNB
cik: 0000921299
company_name: KYNTRA BIO, INC.
filed_at: 2026-01-07T23:59:59+00:00
discovered_at: 2026-05-14T18:02:38.036540+00:00
generated_at: 2026-05-16T11:29:09.753253+00:00
sec_items: ["5.03", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-006327
json_url: https://secwatch.observer/filing/0001193125-26-006327.json
markdown_url: https://secwatch.observer/filing/0001193125-26-006327.md
text_url: https://secwatch.observer/filing/0001193125-26-006327.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/fgen-20260107.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

0cdf713694d65e36548c2b695c3ced91598752fd

KYNTRA BIO, INC.: Amended certificate of incorporation to change company name from FibroGen, Inc. to Kyntra Bio, Inc (effective 2026-01-07).

On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

2e432c168d52cef62c8cde2aa70caa84647445a0

KYNTRA BIO, INC.: Amended bylaws solely to update the title to reflect the company's new name, Kyntra Bio, Inc (effective 2026-01-07).

The Board also approved the amendment of the Company’s Bylaws, effective at 4:30 p.m. Eastern Time on January 7, 2026, solely to update the title of the Bylaws to reflect the Company’s new name, Kyntra Bio, Inc.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.

Comparable filing

On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.

Filing page SEC filing

SAGU

Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE

Shreya Acquisition Group May 11, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.

Comparable filing

On May 6, 2026, and in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association.

Filing page SEC filing

ADT

Apollo sells all 102M ADT shares; ADT repurchases 29.1M shares in $1.5B plan

ADT Inc. May 8, 2026, 7:59 PM ET other_material Items 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.

Comparable filing

On May 8, 2026, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, dated as of September 15, 2023 (as amended, the “ Bylaws ”), to remove references related to Apollo and the Amended and Restated Stockholders Agreement, dated December 14, 2018, between the Company, Prime Security Services TopCo Parent, L.P., and the Co-Investors.

Filing page SEC filing

BNZI

Banzai announces 1-for-20 reverse stock split effective May 8, 2026 to maintain Nasdaq compliance

Banzai International, Inc. May 6, 2026, 7:59 PM ET other_material Items 3.03, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.

Comparable filing

On April 28, 2026, the Company filed a Certificate of Amendment to its COI with the Secretary of State of Delaware (the “Certificate of Amendment”), for the Reverse Stock Split at a ratio of 1-for-20.

Filing page SEC filing

QLEP

Quantum Leap Acquisition Corp closes $200M SPAC IPO on NYSE

Quantum Leap Acquisition Corp May 6, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.

Comparable filing

In connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies. The Amended and Restated Memorandum and Articles of Association have an effective date of April 29, 2026, being the date on which the special resolution to adopt the Amended and Restated Memorandum and Articles of Association was passed.

Filing page SEC filing

MCAH

Mountain Crest Acquisition 6 Corp. closes $60M IPO; units start trading April 30

Mountain Crest Acquisition 6 Corp. May 5, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.

Comparable filing

On April 29, 2026, in connection with the IPO, the Company filed its Amended and Restated Memorandum and Articles of Association, as described in the Registration Statement, with the Registry of Corporate Affairs of British Virgin Islands.

Filing page SEC filing

COAG

Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M

Hemab Therapeutics Holdings, Inc. May 4, 2026, 7:59 PM ET other_material Items 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.

Comparable filing

On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).

Filing page SEC filing

CAII

Collective Acquisition Corp. II closes $220M IPO; units trade on Nasdaq

Collective Acquisition Corp. II May 4, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.

Comparable filing

On April 28, 2026, in connection with the Offering, the Company filed its amended and restated memorandum and articles of association (the “ Amended and Restated Memorandum and Articles of Association ”) with the Cayman Islands Registrar of Companies, which became effective on April 28, 2026.

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-006327

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.